Compare SPGI & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPGI | TMO |
|---|---|---|
| Founded | 1860 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5B | 176.8B |
| IPO Year | 1994 | 1996 |
| Metric | SPGI | TMO |
|---|---|---|
| Price | $427.32 | $464.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 19 |
| Target Price | $567.73 | ★ $639.83 |
| AVG Volume (30 Days) | ★ 2.2M | 1.8M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.90% | 0.36% |
| EPS Growth | ★ 18.70 | 7.32 |
| EPS | 14.66 | ★ 17.74 |
| Revenue | $6,063,000,000.00 | ★ $20,918,000,000.00 |
| Revenue This Year | $9.70 | $6.22 |
| Revenue Next Year | $7.36 | $5.10 |
| P/E Ratio | $29.61 | ★ $26.61 |
| Revenue Growth | 7.10 | ★ 14.47 |
| 52 Week Low | $381.61 | $385.46 |
| 52 Week High | $579.05 | $643.99 |
| Indicator | SPGI | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 25.75 |
| Support Level | $415.92 | $451.48 |
| Resistance Level | $451.66 | $497.64 |
| Average True Range (ATR) | 9.11 | 12.60 |
| MACD | 1.76 | -1.90 |
| Stochastic Oscillator | 32.15 | 1.16 |
S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include commodity insights (Platts and other data), mobility (Carfax), and indexes.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).